A phenol derivative of the formula NU-A-X-R1 wherein NU is a defined bis-phenolic nucleus including a hydroxyphenyl-hydroxynaphthyl; hydroxyphenyl-hydroxy-indanyl hydroxyphenyl-hydroxybenzothienyl or di-hydroxyphenyl-ethylene or vinylene nucleus; wherein A is alkylene alkenylene or cycloalkylene which is interrupted by a heterocyclene linkage wherein R1 is hydrogen or alkyl alkenyl cycloalkyl halogenoalkyl aryl or arylalkyl or R1 is joined to R2 and wherein X is -CONR2- -CSNR2- -NR12CO- -NR12CS-...

A phenol derivative of the formula NU-A-X-R1 wherein NU is a defined bis-phenolic nucleus including a hydroxyphenyl-hydroxynaphthyl; hydroxyphenyl-hydroxyindanyl hydroxyphenyl-hydroxybenzothienyl or di-hydroxyphenyl-ethylene or vinylene nucleus; wherein A is alkylene alkenylene or alkynylene which may be interrupted by phenylene or other linkages wherein R1 is hydrogen or alkyl alkenyl cycloalkyl halogenoalkyl aryl or arylalkyl or R1 is joined to R2 and wherein X is -CONR2- -CSNR2- -NR12CO- -NR1...

This invention relates to enzyme inhibitory novel phthalazin-4-ylacetic acid derivatives of the general formula I: I and pharmaceutically acceptable salts as appropriate to pharmaceutical compositions thereof and to analogy processes for their manufacture.The compounds of formula I are inhibitors of the enzyme aldose reductase in vivo and as such may be useful in the reduction or prevention of the development of the peripheral effects such as macular oedema cataract retinopathy or impaired neu...